Minerva Neurosciences (NASDAQ:NERV) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research note issued to investors on Tuesday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright decreased their price objective on shares of Minerva Neurosciences from $7.00 to $5.00 and set a neutral rating for the company in a research report on Wednesday, August 7th.

Minerva Neurosciences Stock Performance

Minerva Neurosciences stock opened at $2.59 on Tuesday. The firm has a market capitalization of $18.11 million, a PE ratio of -0.58 and a beta of 0.14. Minerva Neurosciences has a one year low of $2.26 and a one year high of $13.49. The stock’s 50 day moving average price is $2.78 and its 200 day moving average price is $2.80.

Minerva Neurosciences (NASDAQ:NERV) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.12). On average, analysts forecast that Minerva Neurosciences will post -2.26 earnings per share for the current fiscal year.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.